Hyderabad: For those who are still a tad hesitant in taking the Covaxin jab, there’s reassuring news.
The phase 3 interim analysis of the Bharat Biotech-manufactured coronavirus vaccine was announced on Wednesday. And it points to 78% efficacy against mild, moderate, and severe COVID-19 disease.
The second interim analysis is based on records of 127 symptomatic cases.
The efficacy against severe coronavirus cases was 100%, with an impact on reduction in hospitalizations, while the efficacy against asymptomatic COVID-19 infection was 70%.
Safety and efficacy results from the final analysis will be available in June.
A total of 25,800 participants, between 18-98 years of age, had enrolled for phase 3 trials of Covaxin. Of those, 10% was over the age of 60, whose analysis was conducted 14 days after administration of second dose.
“Efficacy against SARS-Cov-2 has been established. COVAXIN has demonstrated an excellent safety record in human clinical trials and in usage under emergency use. COVAXIN is now a global innovator vaccine derived from Research & Development from India. The efficacy data against severe COVID-19 and asymptomatic infections is highly significant, as this helps reduce hospitalizations and disease transmission, respectively,” said Bharat Biotech’s Chairman & Managing Director Dr Krishna Ella.